Explore Our
   Virtual Medical Booth
Filtered (2)
Filters
Apply Reset
Topic
Forum
Year
Show (2)
Cancel
Apply Reset

Showing 2 out of 2

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK

ASCIA 2022

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

EAACI 2022

About

Management team

Board of Directors

Science

Pipeline

Sebetralstat

Oral Factor XIIa Inhibitor

Careers

Job Openings

Contact

KalVista Terms of Use Privacy Policy
© 2024 KalVista Pharmaceuticals. All Rights Reserved.